Literature DB >> 35899627

Time from diagnosis to treatment is associated with survival in patients with acute myeloid leukaemia: An analysis of 55 985 patients from the National Cancer Database.

Aseel Alsouqi1, Scott D Rothenberger2,3, Michael Boyiadzis4, Konstantinos Lontos1.   

Abstract

Acute myeloid leukaemia (AML) is conventionally thought of as a medical emergency. However, several studies on the association of time from diagnosis to treatment with survival did not have concordant results. Here we analyse 55 985 AML patients from the National Cancer Database, and we show that in patients less than 60 years old a five-day delay in chemotherapy initiation leads to worse long-term survival. The difference is small [hazard ratio (HR) 1.05, 95% confidence interval (CI) 1.01-1.09 in multivariate analysis] but statistically significant. This study raises the issue of power to detect small differences in retrospective studies.
© 2022 British Society for Haematology and John Wiley & Sons Ltd.

Entities:  

Keywords:  acute myeloid leukaemia; time from diagnosis to treatment; time to treatment

Mesh:

Year:  2022        PMID: 35899627      PMCID: PMC9547942          DOI: 10.1111/bjh.18381

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   8.615


  8 in total

1.  A study of the natural history of acute leukemia with special reference to the duration of the disease and the occurrence of remissions.

Authors:  C M SOUTHAM; L F CRAVER; H W DARGEON; J H BURCHENAL
Journal:  Cancer       Date:  1951-01       Impact factor: 6.860

2.  Absolute risk reductions and numbers needed to treat can be obtained from adjusted survival models for time-to-event outcomes.

Authors:  Peter C Austin
Journal:  J Clin Epidemiol       Date:  2009-07-12       Impact factor: 6.437

3.  Impact of treatment delay in acute myeloid leukemia revisited.

Authors:  Gunnar Juliusson; Oskar Hagberg; Vladimir Lj Lazarevic; Sören Lehmann; Martin Höglund
Journal:  Blood Adv       Date:  2021-02-09

4.  Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?

Authors:  Christoph Röllig; Michael Kramer; Christoph Schliemann; Jan-Henrik Mikesch; Björn Steffen; Alwin Krämer; Richard Noppeney; Kerstin Schäfer-Eckart; Stefan W Krause; Mathias Hänel; Regina Herbst; Volker Kunzmann; Hermann Einsele; Edgar Jost; Tim H Brümmendorf; Sebastian Scholl; Andreas Hochhaus; Andreas Neubauer; Kristina Sohlbach; Lars Fransecky; Martin Kaufmann; Dirk Niemann; Markus Schaich; Norbert Frickhofen; Alexander Kiani; Frank Heits; Ulrich Krümpelmann; Ulrich Kaiser; Johannes Kullmer; Maxi Wass; Friedrich Stölzel; Malte von Bonin; Jan Moritz Middeke; Christian Thiede; Johannes Schetelig; Wolfgang E Berdel; Gerhard Ehninger; Claudia D Baldus; Carsten Müller-Tidow; Uwe Platzbecker; Hubert Serve; Martin Bornhäuser
Journal:  Blood       Date:  2020-08-13       Impact factor: 22.113

5.  Age and acute myeloid leukemia.

Authors:  Frederick R Appelbaum; Holly Gundacker; David R Head; Marilyn L Slovak; Cheryl L Willman; John E Godwin; Jeanne E Anderson; Stephen H Petersdorf
Journal:  Blood       Date:  2006-02-02       Impact factor: 22.113

6.  Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.

Authors:  Richard M Stone; Sumithra J Mandrekar; Ben L Sanford; Kristina Laumann; Susan Geyer; Clara D Bloomfield; Christian Thiede; Thomas W Prior; Konstanze Döhner; Guido Marcucci; Francesco Lo-Coco; Rebecca B Klisovic; Andrew Wei; Jorge Sierra; Miguel A Sanz; Joseph M Brandwein; Theo de Witte; Dietger Niederwieser; Frederick R Appelbaum; Bruno C Medeiros; Martin S Tallman; Jürgen Krauter; Richard F Schlenk; Arnold Ganser; Hubert Serve; Gerhard Ehninger; Sergio Amadori; Richard A Larson; Hartmut Döhner
Journal:  N Engl J Med       Date:  2017-06-23       Impact factor: 91.245

7.  Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients.

Authors:  Mikkael A Sekeres; Paul Elson; Matt E Kalaycio; Anjali S Advani; Edward A Copelan; Stefan Faderl; Hagop M Kantarjian; Elihu Estey
Journal:  Blood       Date:  2008-09-30       Impact factor: 22.113

8.  Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia.

Authors:  Sarah Bertoli; Emilie Bérard; Françoise Huguet; Anne Huynh; Suzanne Tavitian; François Vergez; Sophie Dobbelstein; Nicole Dastugue; Véronique Mansat-De Mas; Eric Delabesse; Eliane Duchayne; Cécile Demur; Audrey Sarry; Valérie Lauwers-Cances; Guy Laurent; Michel Attal; Christian Récher
Journal:  Blood       Date:  2013-01-30       Impact factor: 22.113

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.